MS Trust Shop Natalizumab (Tysabri) - factsheet

In 2007, both NICE (in England and Wales) and the SMC (in Scotland) recommended natalizumab (Tysabri) as an option for the treatment of rapidly evolving severe relapsing-remitting multiple sclerosis.

Our factsheet discusses the research into the drug, the reasons why its use is limited to people with a certain type of MS and the decisions of the appraisal bodies.

Return